Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in ALS (MERIDIAN)
NCT04579666Phase 2Terminated
- Sponsor
- Apellis Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- PEGylated Peptides
- Countries
- 14
01
Overview
A Phase 2 trial of pegcetacoplan in amyotrophic lateral sclerosis (ALS), sponsored by Apellis Pharmaceuticals. Started Sep 2020; status: terminated.
02
Drugs
pegcetacoplan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04579666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04579666.